PMV Pharma Reports 46% ORR in Ovarian Cancer Cohort, Plans NDA Filing in Q1 2027
PMVP is trading near its 52-week low of $1.02 (0.2% above the low) on elevated volume (1.8× avg).
Summary
PMV Pharma announced promising updated ovarian cancer data from its pivotal PYNNACLE trial and confirmed plans to submit an NDA for accelerated approval in Q1 2027.
Key Events · Product Development and Regulatory · PMVP
-
46% ORR in Ovarian Cancer Cohort
Updated interim data from the Phase 2 pivotal PYNNACLE trial showed a 46% overall response rate (35/76 evaluable patients) in platinum-resistant/refractory ovarian cancer, including 4 confirmed complete responses and 29 confirmed partial responses.
-
Median Duration of Response 10 Months
Median duration of response was 10.0 months based on confirmed responses only, with median time to response of 1.3 months.
-
FDA Supports Accelerated Approval Path
Recent FDA interaction supports the NDA submission strategy for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer with a TP53 Y220C mutation.
-
NDA Submission Planned Q1 2027
Company anticipates submitting the New Drug Application in the first quarter of 2027, with a full update on all PYNNACLE Phase 2 cohorts at a medical conference in Q4 2026.
Analysis · PMVP · Life Sciences
Updated interim data from the pivotal PYNNACLE trial revealed a 46% overall response rate in platinum-resistant/refractory ovarian cancer patients, with a median duration of response of 10 months. The company also confirmed FDA feedback supporting an accelerated approval NDA submission planned for Q1 2027. This is a meaningful clinical milestone for a company trading near its 52-week low with a going concern warning and less than one year of cash runway — positive data and a clear regulatory path could materially improve its financing and partnership prospects.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1838 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PMVP was trading at $1.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $64.7M. The 52-week trading range was $1.02 to $1.88. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.